2023
Early B cell tolerance defects in anti-neurofascin 155 mediated chronic inflammatory demyelinating polyneuropathy (S40.005)
Roy B, Obaid A, Ohashi S, Coppola C, Das S, Hernandez A, Masi G, Martin-Aguilar L, Lleixà M, Nowak R, Querol Gutierrez L, O’Connor K. Early B cell tolerance defects in anti-neurofascin 155 mediated chronic inflammatory demyelinating polyneuropathy (S40.005). Neurology 2023, 100 DOI: 10.1212/wnl.0000000000203364.Peer-Reviewed Original ResearchChronic inflammatory demyelinating polyneuropathyB cell tolerance defectsInflammatory demyelinating polyneuropathyDemyelinating polyneuropathyTolerance defectsPolyneuropathy
2017
Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy
Allen J, Gelinas D, Lewis R, Nowak R, Wolfe G. Optimizing the Use of Outcome Measures in Chronic Inflammatory Demyelinating Polyneuropathy. TouchREVIEWS In Neurology 2017, 13: 26. DOI: 10.17925/usn.2017.13.01.26.Peer-Reviewed Original ResearchChronic inflammatory demyelinating polyneuropathyOverall Disability Sum ScoreOverall Neuropathy Limitations ScaleInflammatory demyelinating polyneuropathyOutcome measuresDemyelinating polyneuropathyDisability scoresMedical Research Council sum scoreSum scoreTreatment (INCAT) disability scoreInflammatory Neuropathy CauseOverall Disability ScaleRoutine daily practiceAssessment of patientsQuality of lifeAspects of impairmentDisability outcomesSensory dysfunctionMartin VigorimeterGrip strengthInflammatory RaschDisability ScaleLimitation ScaleClinical trialsSensory impairment